Platinum-Based Neoadjuvant Chemotherapy Before Radical Prostatectomy for Locally Advanced Prostate Cancer With Homologous Recombination Deficiency: A Case Report

Frontiers in Oncology

Shuyue Ai¹  Yao Fu²  Tingting Zhao⁴  Yining Yang⁴  Junlong Zhuang⁵  Xuefeng Qiu⁵  Shun Zhang⁵  Hongqian Guo⁵ 

[1] Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, China;Department of Pathology, Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China;Department of Urology, Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China;GloriousMed Clinical Laboratory (Shanghai) Co., Ltd., Shanghai, China;Institute of Urology, Nanjing University, Nanjing, China;

关键词: prostate cancer;    neoadjuvant chemotherapy;    platinum;    next-generation sequencing;    homologous recombination defect;   

DOI  :  10.3389/fonc.2021.777318

来源: DOAJ

【 摘 要 】

More emerging evidence showed that homologous recombination (HR) defect (HRD) may predict sensitivity to platinum agents in metastatic prostate cancer (PCa). Platinum-based neoadjuvant chemotherapy for PCa with HRD has not been reported. Here, we reported a man diagnosed as locally advanced PCa with high Gleason Score (5 + 5) and low PSA level (5.2 ng/ml). Next-generation sequencing (NGS) demonstrated HRD. He received six cycles of platinum-based neoadjuvant chemotherapy before radical prostatectomy (RP). Fifteen months after RP, his PSA level was still undetectable, and no imaging progression was found, indicating a potential role for platinum-based neoadjuvant chemotherapy in locally advanced PCa with HRD.

【 授权许可】

Unknown